Akademik Veri Yönetim Sistemi
LATIN AMERICAN JOURNAL OF PHARMACY, cilt.40, sa.10, ss.2330-2336, 2021 (SCI-Expanded)
Sunitinib, a common drug used in cancer treatment, is a multi-targeted tyrosine kinase inhibitor. It is argued that sunitinib-associated oral mucositis is caused by VEGF inhibition. Previous research has documented that ATP allows for wound healing through an increase in VEGF levels and provides an antioxidant effect. The aim of our study was to biochemically analyze whether adenosine triphosphate (ATP) offers any protective effects against potential oral oxidative mucosal damage due to sunitinib use in male albino Wistar rats. ATP was injected ip at 25 mg/kg dose to sunitinib + ATP(SAT) ( n=8) group. Normal saline (0.9% NaCl) was applied in the same route to the sunitinib-alone(SUN) (n=8) and healthy (HG) (n=8) groups as the solvent. One hour after ATP and 0.9% NaCl were administered, oral delivery of 25 mg/kg sunitinib was given to the SAT and SUN groups, once a day for four weeks. While MDA, TOS and 8-OHdG levels were significantly higher (p < 0.001) compared to the healthy and ATP group in the oral cavity tissues of subjects treated with sunitinib, tGSH and TAS were significantly lower (p < 0.001). Our experimental results show that ATP protects tongue and cheek tissues of rats from oxidative damage of sunitinib, indicating that ATP may be beneficial for sunitinib-related oral mucosal injury.